Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

BACKGROUND: Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which stimulate cancer cell proliferation and induce drug resistance. Cross talk between IGF-1R and epidermal growth factor receptor (EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Wahab, Reham, Varadhachary, Gauri R., Bhosale, Priya R., Wang, Xuemei, Fogelman, David R., Shroff, Rachna T., Overman, Michael J., Wolff, Robert A., Javle, Milind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975422/
https://www.ncbi.nlm.nih.gov/pubmed/29843755
http://dx.doi.org/10.1186/s13045-018-0616-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975422/
https://www.ncbi.nlm.nih.gov/pubmed/29843755
http://dx.doi.org/10.1186/s13045-018-0616-2

Ejemplares similares